ClosingWithin 30 Days

Transformative Finance Proof of Concept (Amended)

ID: 9808458-50

Potential Value

$12,000

Deal Value

$0

Stated Probability

100%

Days in Pipeline

376

Client & Account

Client

Wolf Pharmaceutical Inc

City

Houston

Region

USLI

Sub-Sector

SLED

Service Classification

Service Line

Assurance

Field of Play

Audit & Governance

Opportunity Sub-SL

Audit

Competency

Audit (CORE)

Global Service Code

Trade Compliance (46686)

People & Dates

Partner

Martin Kenneth

Pursuit Leader

Anderson Laura

Open Date

May 2, 2025

Anticipated Win Date

May 2, 2026

Close Date

N/A

Details

Description

Transformative Finance Proof of Concept (Amended)

Triage & Expected Value

Triage Model: P(Pursue)

Predicts likelihood of pursuit vs. decline

P(Pursue)

97.8%

Expected Value (EV = P(Pursue) × P(Win) × Value)

$11,601

Key Triage Drivers

Work type
+0.827
Non-recurring work
+0.672
Service sub-line track record
+0.551

Win Probability Models

P(Pursue)

97.8%

Model A: Planning

98.8%

Model B: Early Signal

89.3%

Stated Probability

100%

Model A: Planning

Includes deal age and timeline factors. Best for active pipeline management.

Win Probability

98.8%

Key Drivers

Brand new pursuit (vs renewal)
+1.507
Lead sales credit %
-0.956
Market segment
-0.604

Plain English

The model a: planning estimates a high probability of winning (99%). Factors working in favor: brand new pursuit (vs renewal). Factors working against: lead sales credit %, market segment.

Model B: Early Signal

Excludes timeline factors. Better for early-stage assessment.

Win Probability

89.3%

Key Drivers

Brand new pursuit (vs renewal)
+0.728
Market segment
-0.622
Account business unit
-0.618

Plain English

The model b: early signal estimates a high probability of winning (89%). Factors working in favor: brand new pursuit (vs renewal). Factors working against: market segment, account business unit.